Overcoming Formulation Challenges for Complex Bispecific Antibody Drug Product Development

Dr. Xiaofeng Lu is a principal scientist in the Drug Product Development, CMC Biologics group at AbbVie in South San Francisco, CA. Her primary work involves end-to-end pharmaceutical development, including liquid and lyophilized formulation development, drug product process development, and technology transfer for manufacturing biologics. In the recent years, her research interests include complex multi-specific antibodies and antibody drug conjugates (ADCs) stability studies and characterization, formulation and process optimization, drug product configuration development, as well as clinical in-use studies to guide drug dose preparation and administration instructions for clinical trials.